GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 233 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $254,183,000 | +113.1% | 3,732,502 | 0.0% | 1.66% | +145.9% |
| Q2 2022 | $119,253,000 | +3.9% | 3,732,502 | +12.6% | 0.68% | +2.6% |
| Q1 2022 | $114,823,000 | +18.3% | 3,314,765 | 0.0% | 0.66% | +39.8% |
| Q4 2021 | $97,023,000 | +18.3% | 3,314,765 | +3.0% | 0.47% | +31.1% |
| Q3 2021 | $81,980,000 | -27.2% | 3,217,441 | 0.0% | 0.36% | -27.3% |
| Q2 2021 | $112,675,000 | -14.1% | 3,217,441 | 0.0% | 0.50% | -12.9% |
| Q1 2021 | $131,111,000 | +228.9% | 3,217,441 | +249.6% | 0.57% | +278.7% |
| Q4 2020 | $39,861,000 | -21.5% | 920,375 | 0.0% | 0.15% | -26.1% |
| Q3 2020 | $50,749,000 | +1610.4% | 920,375 | +1858.2% | 0.20% | +1461.5% |
| Q2 2020 | $2,967,000 | +23.6% | 47,000 | 0.0% | 0.01% | -13.3% |
| Q1 2020 | $2,401,000 | -74.8% | 47,000 | -92.2% | 0.02% | -85.0% |
| Q1 2016 | $9,516,000 | -26.4% | 600,000 | +50.0% | 0.10% | -6.5% |
| Q4 2015 | $12,932,000 | +53.4% | 400,000 | +100.0% | 0.11% | +37.2% |
| Q3 2015 | $8,432,000 | – | 200,000 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |